Mustang Bio Presents Favorable Phase 1/2 MB-106 Clinical Trial Data at EHA2024

DENVER, Colo., Jun 17, 2024 ( Mustang Bio, Inc. (Nasdaq:MBIO) presented positive updated data from its ongoing Phase 1/2 MB-106, a CD20-targeted, autologous CAR T-cell therapy, clinical trial, which shows a favorable safety and efficacy profile in patients with Waldenstrom macroglobulinemia (“WM”), a rare form of blood cancer, at the European Hematology Association 2024 Hybrid Congress (EHA2024).

Brian Till, M.D., Associate Professor and physician at Fred Hutch and University of Washington, stated, “We are very encouraged by the safety and efficacy data generated in WM, along with improvements in the quality of responses over time, which demonstrates MB-106 CAR T-cell expansion and persistence.”

About 24/7 Market News
As a pioneer in digital financial market media, 24/7 Market News (24/7MN) is dedicated to the swift distribution of financial market news and information. 24/7 MN incorporates comprehensive corporate communications resources and tools to engage the investment community. Visit 24/7 Market News website here.

24/7 MARKET NEWS, INC Disclaimer
Please go to for disclaimer information.

24/7 Market News
[email protected]

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.